KymaThera

Develops K-1728, a therapy for HR-positive, HER2-negative breast cancer.

Health and bioHR and recruiting

KymaThera raised $80M in a Series B+ round announced October 6, 2026, according to citybiz.co.

Raise history

1. October 6, 2026
   Series B+ · $80M
   Source: citybiz.co
2. December 18, 2023
   Website created

Related bio health companies

• SSunfox$7M · Oct 7, 2026
• AAlteogen$150M · Oct 6, 2026
• SSynvareOct 6, 2026
• SSuperMush$3M · Oct 6, 2026
• RRougeTx$58M · Oct 6, 2026
• AArcheon Medical$9M · Oct 6, 2026
• AArboretum$30M · Oct 6, 2026
• CCureMeAbroad$1.1M · Oct 6, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/kymathera.